Diabetes & Metabolism

Three research scientists, including a nephrologist, awarded Nobel Prize in Medicine for work with how cells sense and adapt to oxygen

Announced on October 7th, the Nobel Prize in Medicine was jointly awarded to a trio of scientists, William G. Kaelin Jr., Peter J. Ratcliffe, and Gregg L. Semenza, for their work on “how cells sense and adapt to oxygen availability,” The New York Times reports.

These “investigators uncovered detailed genetic responses to changing oxygen levels that allow cells in the bodies of humans and other animals sense and respond to fluctuations, increasing and decreasing how much oxygen they receive.”

FDA approves first new treatment in 20 years to treat diabetic kidney disease and reduce the risk of hospitalization for heart failure

The U.S. FDA has now approved INVOKANA® (canagliflozin) as the only type 2 diabetes (T2D) medicine indicated to treat diabetic kidney disease (DKD) and reduce the risk of hospitalization for heart failure in patients with T2D and DKD.  Approximately 1 in 3 patients with T2D also has DKD, which can ultimately lead to kidney failure. Once patients reach kidney failure, the average 5-year survival is less than 40%, largely due to cardiovascular-associated morbidity and mortality.

KHI Technology Roadmap for Innovative Approaches to Kidney Replacement Therapies

With the aid of patients, care partners, and multiple academic, private, and public communities, the Kidney Health Initiative’s newly developed technology roadmap is catalyzing innovative approaches to kidney replacement therapy (KRT). The roadmap provides guidance for innovators and entrepreneurs who are working to redesign dialysis and provide better care for those with kidney disease.

ASN Weighs in on ESRD Treatment Choice Model in Letter to CMS

Reducing the benchmark for the combined home dialysis and transplant rate and allowing for incremental achievement of the benchmark, incentivizing and investing wisely to ensure needed practice transformation, and delaying the start date of the ESRD Treatment Choice Model (ETC) until April 2020 are among the recommendations for adjustments to the model set forth in a letter sent to CMS Administrator Seema Verma on behalf of ASN and its members from President Mark E. Rosenberg, MD, FASN.

New NephSAP Issue - "Chronic Kidney Disease and Progression"

NephSAP Volume 18, Number 4, September 2019

Chronic Kidney Disease and Progression

Interview with Dr. Michael Allon, editor-in-chief of Kidney360, on new ideas for the journal

allon-michael2_1.jpgKidney News Online (KNO) recently spoke with Michael Allon, MD, the inaugural Editor-in-Chief for the newest journal from the American Society of Nephrology, Kidney360. As the open access, online only journal began accepting manuscripts on October 1st, KNO wanted to learn more about the ideas behind the new journal.

 

Advancing Nephrology: Division Leaders Advise ASN

Asserting the value of nephrology

Physician productivity and compensation

Financial support of educational effort

Recruitment, retention, diversity and inclusion

Ensuring that Nephrology fellowship programs provide quality training in all aspects of kidney care

ASN Policy Q&A on the Advancing American Kidney Health initiative: Part 2

In order to double the number of kidneys available for transplant by 2030, the Administration is looking to increase the utilization of available organs from both deceased and living donors in multiple ways including, but not limited to:...

Diabetes and Kidney Disease 2019: August Special Section

Capture_title_0.PNGDiabetes is the second most common cause of kidney failure in the United States. Diabetic Kidney Disease (DKD) encompasses structural and functional abnormalities involving the kidneys. Clinically, these changes result in hypertension, proteinuria, and progressive decline in kidney function, ultimately leading to ESKD. Diabetic kidney disease accounts for more than 40% of all ESKD In the United States.

Dr. Reshma Kewalramani named incoming president and CEO of Vertex Pharmaceuticals, former member ASN KHI Board of Directors

Announced July 25, Dr. Reshma Kewalramani will be promoted to president and CEO of Vertex Pharmaceuticals. She is currently the chief medical officer for the company and was previously a practicing nephrologist who earned her medical doctorate at Boston University and trained at Bigham & Women’s Hospital.

Dr. Kewalramani will be the first woman to run a large biotechnology firm. Vortex’s share price “rose 360% and its sales doubled to $3 billion annually” under the previous CEO, largely due the company’s pharmaceuticals used to treat cystic fibrosis.

Pages